Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 13, 2023

BUY
$43.24 - $61.04 $117,483 - $165,845
2,717 Added 40.13%
9,487 $0
Q3 2022

Oct 19, 2022

BUY
$44.76 - $69.66 $303,025 - $471,598
6,770 New
6,770 $392,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Harbour Capital Advisors, LLC Portfolio

Follow Harbour Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbour Capital Advisors, LLC with notifications on news.